Medinsight Decisions in Health Care
• Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario. The International Journal of Atherosclerosis 2007; 2(3)189-94. Disponível em: http://www.ijathero.com/2007/september
• Análise econômica do uso de cetuximabe no tratamento de pacientes com carcinoma de células escamosas de cabeça e pescoço localmente avançado. Revista das Sociedades Brasileiras de Câncer 2007;4(16):21-6.
• Custo-efetividade da trombólise pré-hospitalar vs intra-hospitalar no Infarto Agudo do Miocárdio. Arq Bras Cardiol 2008;90(2): 100-7. Disponível em: www.arquivosonline.com.br/2008/9002
• Cost-effectiveness analysis of zoledronic acid versus risedronate for the prevention of osteoporotic hip fracture in the private health care system in Brazil. Value in Health 2008;11(3):A29-A311.
• Análise de custo-efetividade do peptídeo natriurético tipo-B comparado ao julgamento clínico em pacientes com dispnéia aguda no Sistema Único de Saúde. Rev SOCERJ. 2008;21(4):217-25.
• Complications risk estimation in type 2 diabetes by glycemic control in a population from a private health care insurance in Brazil: a ten-year simulation analysis using Monte Carlo Model (ISPOR 1st Latin America Conference Research. 2007 Abstract ID# 15262).
• Análise de custo-efetividade do ácido zoledrônico na prevenção da fratura osteoporótica proximal de fêmur no cenário do Sistema Suplementar de Saúde Brasileiro. Rev Bras Geriatr Gerontol 2008; 11(3): 357-68.
• Análise econômica do uso de cetuximabe no tratamento de pacientes com carcinoma de células escamosas de cabeça e pescoço localmente avançado. Revista das Sociedades Brasileiras de Câncer 2007;4(16):21-6.
• Custo-efetividade da trombólise pré-hospitalar vs intra-hospitalar no Infarto Agudo do Miocárdio. Arq Bras Cardiol 2008;90(2): 100-7. Disponível em: www.arquivosonline.com.br/2008/9002
• Cost-effectiveness analysis of zoledronic acid versus risedronate for the prevention of osteoporotic hip fracture in the private health care system in Brazil. Value in Health 2008;11(3):A29-A311.
• Análise de custo-efetividade do peptídeo natriurético tipo-B comparado ao julgamento clínico em pacientes com dispnéia aguda no Sistema Único de Saúde. Rev SOCERJ. 2008;21(4):217-25.
• Complications risk estimation in type 2 diabetes by glycemic control in a population from a private health care insurance in Brazil: a ten-year simulation analysis using Monte Carlo Model (ISPOR 1st Latin America Conference Research. 2007 Abstract ID# 15262).
• Análise de custo-efetividade do ácido zoledrônico na prevenção da fratura osteoporótica proximal de fêmur no cenário do Sistema Suplementar de Saúde Brasileiro. Rev Bras Geriatr Gerontol 2008; 11(3): 357-68.
• Prevalência de dismenorréia primária e seu impacto sobre a produtividade em mulheres brasileiras - Estudo DISAB. Revista Brasileira de Medicina. 2008;65(8):250-253.
• Estimated incidence of testosterone deficiency in aging Brazilian men and the consequent costs of new cases of osteoporosis-related hip fractures. Poster presentation - ISPOR 11th Annual European Congress, November 2008, pgA498 PDB9 - Athens, Greece.
• Economic evaluation of paliperidone ER for the treatment of schizophrenia in the context of Brazilian Public Health Care System. ISPOR 11th Annual European Congress, November 2008, pgA585 PMH20 - Athens, Greece.
• Palliative care for cancer patients in Brazil: A cost-of-illness study. Poster presentation - ISPOR 11th Annual European Congress, November 2008, pgA477 PCN57 - Athens, Greece.
• Prediction model for new cases of metabolic syndrome and type 2 diabetes mellitus based on an estimated incidence of testosterone deficiency in aging Brazilian men. Poster presentation - ICE 2008.
• Tratamento Inicial da Fibrilação Atrial Aguda no Sistema Único de Saúde: Análise de Custo-Efetividade e Impacto Orçamentário da Propafenona versus Amiodarona. Congresso SOBRAC, 2008. Salvador.
• Evaluation of the economic impact of pneumococcal disease and the cost-effectiveness of pneumococcal conjugate vaccination in Brazil. Pan American Journal of Public Health 2009 (in press).
• Estimated incidence of testosterone deficiency in aging Brazilian men and the consequent costs of new cases of osteoporosis-related hip fractures. Poster presentation - ISPOR 11th Annual European Congress, November 2008, pgA498 PDB9 - Athens, Greece.
• Economic evaluation of paliperidone ER for the treatment of schizophrenia in the context of Brazilian Public Health Care System. ISPOR 11th Annual European Congress, November 2008, pgA585 PMH20 - Athens, Greece.
• Palliative care for cancer patients in Brazil: A cost-of-illness study. Poster presentation - ISPOR 11th Annual European Congress, November 2008, pgA477 PCN57 - Athens, Greece.
• Prediction model for new cases of metabolic syndrome and type 2 diabetes mellitus based on an estimated incidence of testosterone deficiency in aging Brazilian men. Poster presentation - ICE 2008.
• Tratamento Inicial da Fibrilação Atrial Aguda no Sistema Único de Saúde: Análise de Custo-Efetividade e Impacto Orçamentário da Propafenona versus Amiodarona. Congresso SOBRAC, 2008. Salvador.
• Evaluation of the economic impact of pneumococcal disease and the cost-effectiveness of pneumococcal conjugate vaccination in Brazil. Pan American Journal of Public Health 2009 (in press).